RxMD signs drug development agreement with GlycoRegImmune
As per the terms of the agreement, RxMD will use its drug development expertise for enhancing GRI’s line of drugs. GRI CEO Marc Hertz said they now have
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.